Literature DB >> 3485019

Circulating antibodies to mouse monoclonal immunoglobulins in normal subjects--incidence, species specificity, and effects on a two-site assay for creatine kinase-MB isoenzyme.

R J Thompson, A P Jackson, N Langlois.   

Abstract

With a two-site CK-MB assay, we screened serum samples from 1008 blood donors for the presence of antibodies to mouse monoclonal immunoglobulin. These antibodies were capable of cross-linking the labeled antibody with the solid-phase antibody in the two-site assay, thus generating a falsely high apparent CK-MB concentration. In 92 (9.12%) of the blood donors tested, apparent CK-MB concentrations of 10-1000 micrograms/L decreased to less than 3 micrograms/L when re-assayed with non-immune mouse serum (10 mL/L) included in the assay reagent. We tested the ability of non-immune sera from other animal species to lower the concentration of apparent CK-MB in 58 of the 92 samples. Bovine and ovine serum were almost as effective as mouse serum; feline, canine, and rabbit serum were less effective. Of the samples tested, 12% (1.1% of the original population screened) showed apparent CK-MB values that either were not depressed by bovine serum or were only partly depressed. We discuss the possible etiology of these antibodies in normal subjects and recommend that all mouse monoclonal two-site assays should contain non-immune mouse serum (or a suitable "irrelevant" mouse monoclonal antibody) to prevent false-positive results.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485019

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  15 in total

1.  Heterophile antibody interference in a multiplexed fluorescent microsphere immunoassay for quantitation of cytokines in human serum.

Authors:  Thomas B Martins; Brian M Pasi; Christine M Litwin; Harry R Hill
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

2.  The incidence of non-iatrogenic human anti-mouse antibodies and their possible clinical relevance.

Authors:  R W Lipp; A Passath; G Leb
Journal:  Eur J Nucl Med       Date:  1991

3.  False serum calcitonin high levels using a non-competitive two-site IRMA.

Authors:  M Tommasi; A Brocchi; A Cappellini; S Raspanti; M Mannelli
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

4.  Evaluation of anti-C1q capture assay for detecting circulating immune complexes and comparison with polyethylene glycol-immunoglobulin G, C1q-binding, and Raji cell methods.

Authors:  S S Levinson; J O Goldman
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

5.  Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific?

Authors:  F Perosa; R Rizzi; V Pulpito; F Dammacco
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

6.  Chemotherapy of a patient because of spuriously elevated alpha-fetoprotein levels. Identification of the responsible factor.

Authors:  N Dahlmann; J H Hartlapp
Journal:  Klin Wochenschr       Date:  1989-04-03

7.  Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies.

Authors:  A Mittelman; Z J Chen; T Kageshita; H Yang; M Yamada; P Baskind; N Goldberg; C Puccio; T Ahmed; Z Arlin
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

8.  Interference in thyrotropin (TSH) determination: falsely elevated TSH values in a transplanted patient.

Authors:  J Seghers; F Schrurs; P De Nayer; C Beckers
Journal:  Eur J Nucl Med       Date:  1989

9.  Assay interference leading to misdiagnosis of central precocious puberty.

Authors:  David G Segal; Linda A DiMeglio; Kenneth W Ryder; Pamela A Vollmer; Ora Hirsch Pescovitz
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

Review 10.  Human chorionic gonadotrophin and sport.

Authors:  A T Kicman; R V Brooks; D A Cowan
Journal:  Br J Sports Med       Date:  1991-06       Impact factor: 13.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.